The in situ vaccine CpG+OX40 generated the strongest anti-tumor response, significantly slowing tumor progression, improving survival compared to PBS and OX40, and curing significantly more mice than PBS and OX40 (Figures 1A–D). This evidence concerns the gene TNFRSF4 and neoplasm.